ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
The efficacy and safety of the XEN63 glaucoma gel stent without Mitomycin C over the first 10 years.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLong-term data regarding filtering minimally invasive glaucoma surgery remain scarce. Therefore, this study aimed to evaluate the 10-years long-term efficacy and safety of the XEN63 implant (63µm inner diameter, Aquesys Inc./AbbVie Plc).
methodsThis prospective, monocentric longitudinal study included 28 eyes of 26 patients with open angle glaucoma. Implantation of the XEN63 implant was performed at a tertiary study center either as solo procedure or combined with cataract surgery. Notably, neither Mitomycin C nor primary needling was used. Annual examinations of intraocular pressure (IOP), number of IOP-lowering-medications, best-corrected visual acuity (BCVA), visual field mean deviation (VF-MD), complications, surgical success and secondary procedures were analyzed over the first 10 years.
resultsThe preoperative mean IOP of 23.3±4.3mmHg and mean number of IOP-lowering-medications of 3.1±1.1 significantly reduced to 12.8±2.7mmHg and 1.1±1.2, respectively, at 10 years (n=8, p<0.001). 50% (14/28) of all eyes dropped out due to secondary IOP-lowering surgery or explantation until 10 years follow-up. Overall surgical success was achieved in 42% after 8 years and 36% after 10 years, apparently at the expense of 88% (7/8) eyes that required an average of 3.7±2.4 needlings. VF-MD remained stable.
conclusionsXEN63 implantation significantly reduced IOP (-45%) and the number of IOP-lowering-medications (-65%) at the 10 years follow-up. However, limitations must be taken into account here with regard to a potentially attrition effect. A comparison of the results of our early learning curve study population with those reported in the literature on conventional trabeculectomy suggests lower surgical success rates; however, this was accompanied by a comparable need for medications but higher needling rates, while at the same time fewer complications occurred.
Indexed as
Identifiers
42570083What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.